Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic View PDF
Read more
Publication in Cancer Research demonstrates Crescendo Biologics’ Humabody® VH therapeutics outperform conventional antibodies in vivo View PDF
Read more